Remove Blood Pressure Remove Obesity Remove Preserved Ejection Fraction
article thumbnail

Early Renal Denervation Attenuates Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundThe renal sympathetic nervous system modulates systemic blood pressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We

article thumbnail

Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF

Circulation: Heart Failure

BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers.

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52
article thumbnail

Abstract 4139791: A short version of HFD/L-NAME mouse model enabling time-effective proof of concept studies to evaluate drugs targeting the cardiometabolic and mild hypertension associated HFpEF phenotype.

Circulation

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks. in HFD/L-NAME vs E/A=1.4 ± 0.02

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

article thumbnail

Semaglutide Leads to Greater Weight Loss in Women than Men with HF, Improves HF Symptoms in Both Sexes

DAIC

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4

article thumbnail

Association Between Cardiometabolic Comorbidity Burden and Outcomes in Heart Failure

Journal of the American Heart Association

BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2. Journal of the American Heart Association, Ahead of Print.